Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

34 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-19

Study Completion Date

2024-11-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcomas are rare cancers with a high risk of metastatic progression and a major pejorative factor with respect to patient survival. The estimation of the metastatic risk of sarcomas is very complex given the histological heterogeneity of this entity. It is therefore essential that, at diagnosis, a reliable evaluation of this metastatic potential be made, in order to adapt the therapeutic strategy as well as possible.

It has recently been discovered that sarcomas secrete many exosomes that appear to play an important role in tumorogenesis, growth, tumor progression and the onset of metastases. They contain many proteins and nucleic acids (DNA, RNA, microRNA), reflecting the characteristics of the tumor. It has been shown that the amount of exosomes can be correlated with the grade of malignancy of the tumor. Present in the blood, exosomes offer the possibility of non-invasively analyzing the molecular information of the cancer cell. As a result, the study of serum exosomes derived from sarcomas has a high potential as a liquid biopsy to evaluate cancer pathogenesis, progression, and treatment efficacy.

The purpose of this study is to demonstrate in patients with sarcomas that exosomes can be used to monitor their disease and be used as a predictor of the risk of recurrence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

NCT02310451

Metastatic Melanoma

COMPLETED NA

Analysis of Circulating Exosomes in Melanoma Patients

NCT05744076

Melanoma

UNKNOWN

Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults

NCT03670927

Sarcoma Environmental Exposure Occupational Exposure +1 more

COMPLETED

Tracing Dissemination of Melanoma Cells in Healthy Tissues

NCT02854124

Melanoma

COMPLETED

Efficay and Safety of DAROMUN on Patient Treated by Intralesionnal Injection: DAROMEL

NCT07046728

Injections Intralesional

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of this pilot study is to quantify exosomes and analyze their protein and RNA content in patients with sarcoma with disease:

* localized before and after treatment with surgery,
* localized for which neoadjuvant chemotherapy is being considered
* metastatic or locally advanced cancer before and after treatment with first-line chemotherapywhich may include neoadjuvant therapy

The secondary objectives are:

1. Determine whether the initial exosome concentration and the protein and RNA profile they contain vary with the localized or metastatic stage of the disease.
2. Determine if the exosome concentration as well as the protein and RNA profile they contain varies after treatment.
3. Determine if the initial exosome concentration (at T0) is associated with a response to treatment.
4. Determine whether the change in exosome concentration before and after treatment is associated with a response to treatment.
5. Identify a protein marker or RNA associated with a treatment response (marker present at T0 or occurring during follow-up).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Localized sarcoma with neoadjuvant chemotherapy

In total, several blood tests specific to the EXOSARC study will be necessary:

* A first blood test of 7 mL during the initial assessment (inclusion)
* Then four blood samples of 32mL distributed over 6 months

Blood samples

Intervention Type BIOLOGICAL

Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)

Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)

Metastatic or locally advanced sarcoma

In total, several blood tests specific to the EXOSARC study will be necessary :

* A first blood of 7 mL during the initial assessment (inclusion)
* Then three blood samples of 32 mL distribuated over 3 months

Blood samples

Intervention Type BIOLOGICAL

Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)

Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)

Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Localized sarcoma Metastatic sarcoma

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women newly diagnosed with localized, metastatic or locally advanced soft tissue sarcoma
2. Previous treatment of the disease with chemotherapy, radiotherapy or surgery is allowed if it has been completed for more than 12 months at the time of inclusion.
3. For metastatic or locally advanced (inoperable) sarcoma, patients for whom first-line metastatic chemotherapy is indicated.
4. Age ≥18 years
5. Affiliation to a social security scheme
6. Patients who signed informed consent to participate in the study

Exclusion Criteria

Patients who meet at least one of the following criteria will not be eligible:

1. Patient with another synchronous tumor,
2. Patient with sarcoma in irradiated territory
3. Patient with a history of cancer other than sarcoma in the 5 years preceding the diagnosis of sarcoma
4. Patient unable to undergo medical follow-up for geographical, social or psychological reasons,
5. Person benefiting from a protection system for adults (including guardianship and trusteeship),
6. Serology HIV and / or HBV and / or HCV positive.
7. Pregnant or lactating woman.
8. Patients unable to understand, read and / or sign informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No